Yu-tao Liu

发表

Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Yuankai Shi, X. Hao, Lin Yang, 2019, Journal of Hematology & Oncology.

Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.

Jianyang Wang, N. Bi, Tao Zhang, 2021, Annals of palliative medicine.

Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer.

P. Xing, Yuankai Shi, Jun-ling Li, 2019, Journal of thoracic disease.

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients

P. Xing, Yuankai Shi, Dan Wang, 2020, Theranostics.

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

N. Lou, X. Hao, Yu-tao Liu, 2022, Journal of translational medicine.

Sperm-Associated Antigen 9 Assumes Signifying Capacity in Hepatocellular Carcinoma Diagnosis

Yu-tao Liu, Xingsheng Hu, Ke-Qing Yao, 2020 .

First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China

J. Duan, Zhijie Wang, Jie Wang, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

BRAF非V600E突变型肺癌靶向治疗的策略探索

Haitao Yang, Yu-tao Liu, W. Guo, 2022, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

P. Xing, Junling Li, Yan Wang, 2022, BMC Medicine.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

Adjuvant chemotherapy after esophagectomy: Is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?

K. Shao, Jie He, Y. Mao, 2014, Journal of surgical oncology.

Effectiveness of crizotinib in a patient with mesenchymal-epithelial transition overexpression/fluorescence in situ hybridization-negative/next-generation sequencing-negative advanced lung adenocarcinoma: a case report

Tao Zhang, J. Ying, Shugeng Gao, 2019, Translational Cancer Research.

Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients

Junling Li, Yuankai Shi, Yan Wang, 2021, Thoracic cancer.

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

N. Lou, P. Xing, Yuankai Shi, 2021, Cancer Immunology, Immunotherapy.

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases

P. Xing, Junling Li, Yan Wang, 2021, Thoracic cancer.

Prognostic significance of molecular characteristics of cerebrospinal fluid for non‐small cell lung cancer patients with leptomeningeal metastasis

Ning Li, H. Bai, J. Duan, 2019, Thoracic cancer.

Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study

N. Hu, Jinming Yu, Lifeng Wang, 2020, Clinical Cancer Research.

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population

Yuankai Shi, Sheng Yang, Yan Sun, 2014, Translational oncology.

IMPACT: a web server for exploring immunotherapeutic predictive and cancer prognostic biomarkers

S. Cai, J. Duan, Zhijie Wang, 2023, bioRxiv.

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma

D. Lin, Peng Liu, P. Xing, 2019, Front. Oncol..

Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

Jun-ling Li, Yan Wang, X. Hao, 2019, Investigational New Drugs.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

Clinicopathologic characteristics and outcome of patients with different EGFR mutations

Junling Li, Yuankai Shi, Yan Wang, 2018, Asia-Pacific journal of clinical oncology.

Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer.

J. Ying, Weihua Li, Yu-tao Liu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.